Premium
Adjuvant chemotherapy in Ewing's sarcoma
Author(s) -
Advani S. H.,
Rao D. N.,
Dinshaw K. A.,
Nair C. N.,
Gopal R.,
Vyas J. J.,
Desai P. B.
Publication year - 1986
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930320204
Subject(s) - medicine , vincristine , cyclophosphamide , chemotherapy , sarcoma , micrometastasis , adjuvant , ewing's sarcoma , oncology , doxorubicin , adjuvant chemotherapy , surgery , metastasis , pathology , cancer , breast cancer
Adjuvant chemotherapy using vincristine, cyclophosphamide, and adriamycin was used in 28 patients with localized Ewing's sarcoma. Life‐table analysis revealed 55% disease‐free survival at 3 years. in contrast, our historical control showed less than 10% long‐term survival. Adjuvant chemotherapy appears to control both micrometastasis as well as local residual disease. The present study demonstrates the improved survival with adjuvant chemotherapy including adriamycin, vincristine, and cyclophosphamide, in patients with localized Ewing's sarcoma.